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ABSTRACT
Post-herpetic neuralgia is the most frequent complication of herpes zoster and affects up to 30% of
patients. Increased age is a well-recognized risk factor, while the role of gender is highly uncertain. Little
research has been performed into a possible combined effect of age and sex in post-herpetic neuralgia.
The objective of the study was to study the role of age and sex and their combined effect in the
development of post-herpetic neuralgia.
This retrospective study enrolled adult subjects with at least one episode of herpes zoster in the
previous 10 y. A questionnaire on the patient’s socio-demographic, anamnestic and clinical characteristics
was administered by general practitioners. Multivariable logistic regression was used to detect
relationships between post-herpetic neuralgia and age, sex and their interaction.
Fifty-nine of 272 patients reported post-herpetic neuralgia: a prevalence of 21.7%. Subjects with post-herpetic
neuralgia (mean age 70.9 years) were significantly older (P D .001) than those without (64.2 years), the
standardised mean difference being 0.5; no significant between-sex association was revealed
(PD .96). A fully adjusted multivariable logistic analysis, however, revealed a highly significant (PD .007) age-sex
interaction, with an odds ratio of 0.92; this also showed that older males were more likely to report post-herpetic
neuralgia than younger males, while no obvious age-associated pattern was observed among females.
We discerned a significant age-by-sex interaction in the development of post-herpetic neuralgia, which
suggests that the effect of age on the development of this condition may differ between men and women.
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Introduction
Herpes zoster (HZ), or shingles, a secondary infection caused
by the reactivation of latent varicella zoster virus in sensory
ganglia, imposes a significant public health burden. Its annual
incidence is about 3–5/1,000 person-years in the general popu-
lation, and increases to 6–8/1,000 and 8–12/1,000 person-years
among subjects aged 60 and 80 years, respectively.1 Although
HZ-related hospitalization and mortality are relatively low, the
disease, and especially its complications, often seriously affect
patients’ quality of life, thereby engendering high individual
and societal costs. Post-herpetic neuralgia (PHN) is the com-
monest chronic complication of HZ, and occurs as a conse-
quence of peripheral nerve damage during an HZ episode.2
There is no a single definition of PHN, though it is most often
defined as dermatomal pain that persists for at least 3 months
after the onset of HZ rash.1,2 As shown by the systematic review
by Kaway et al,1 the prevalence of PHN among HZ patients
varies between 5% and 30%; the breadth of this range may be
attributed to different study designs and populations. Several
risk factors for the development of PHN in HZ patients have
been cited, including age, sex, clinical characteristics of the HZ
episode, chronic morbidities, immunosuppression, cancer and
others. Among these, older age is the most certain and widely
recognized risk factor, while the role of sex seems to be
controversial. Indeed, some studies have found no association
with sex, others have indicated a greater risk among females,
while still others have discerned a higher risk among males.3
Almost all studies aimed at predicting PHN have used the
regression approach to identify possible risk factors.3 However,
only a few of these have reported testing for possible interactions
between exploratory variables. Interaction occurs when the effect
of one variable depends on the level of another variable, and it
must be considered in any multivariable model, including PHN
studies. Age-gender interaction occurs frequently; for instance, it
has been suggested that the interactive effect of age and sex may
make a significant contribution to pain response.4
Understanding the role of age and sex in PHN is essential, since
they are the primary vaccine-targetable (i.e. may be identified
before an HZ episode) patient characteristics.3 Given the inconclu-
sive results regarding the effect of sex on PHN and the almost total
lack of data on the possible interactive age-by-sex effect, the present
study aimed to gain further insights into the role of age and sex and
their combined effect in the development of PHN.
Results
A total of 276 HZ patients were enrolled. Four patients had no
data on PHN and were therefore excluded from subsequent
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analyses. Females (n D 176, 64.7%) were more numerous than
males (n D 96, 35.3%) and the mean age was 65.6 (SD 15.8)
years. Clinical characteristics of the patients are reported in
Table 1.
The overall prevalence of PHN was 59/272 [21.7% (95% CI:
16.9–27.1%)]. PHN was equally (x2 D 0, P D .96) distributed
among males [21.9% (95% CI: 14.8–31.1%)] and females
[21.6% (95% CI: 16.2–28.2%)]. PHN increased markedly with
age, ranging from 7.7% (95% CI: 2.7–20.3%) in patients under
50 y old to 25.3% (95% CI: 17.3–35.3%) in those aged over 75
y. The mean age of subjects with PHN [70.9 (SD 12.7) years]
was significantly higher tD 3.32, P D .001) than that of subjects
without PHN [64.2 (SD 16.3) years] and the effect size was
medium [d D 0.50 (95% CI: 0.20–0.79)].
In the first model, consisting of only sex, age and their inter-
action term, the main effect of increased age [OR 1.09 (95% CI:
1.04–1.15), P < .001] was a significant predictor of PHN, while
sex was not [OR 1.29 (95% CI: 0.61–2.69), P D .51]. Specifi-
cally, a 1-year increase in age determined a 9.1% increase in the
odds of developing PHN. Moreover, the interaction between
sex and age proved highly significant [OR 0.93 (95% CI: 0.88–
0.98), P D .006]. The fully adjusted model revealed the same
pattern for age [OR 1.09 (95% CI: 1.03–1.16), P D .002], sex
[OR 0.97 (95% CI: 0.41–2.28), P D .94] and their interaction
[OR 0.92 (95% CI: 0.86–0.98), P D .007]. As shown by the
effect plot (Fig. 1), gender impacted the probability of develop-
ing PHN in concomitance with age: older men, were more
likely to suffer from PHN than younger ones, while no obvious
age-related pattern could be seen among women.
Discussion
To our knowledge, this is the first study to find a significant
age-sex interaction in PHN patients. Indeed, in males the risk
increased markedly with age, while no obvious age-related pat-
tern was seen among females. This could partly explain previ-
ously observed inconsistencies in the relationship between
PHN and sex.3
The age-by-sex interaction in PHN was explicitly tested in a
prospective Icelandic study,5 which did not find a significant
association. In that study, however, a much lower prevalence of
PHN was recorded and the study population was significantly
younger. The overall prevalence of PHN observed in our study
was 21.7%; this matched estimates from the pooled analysis of
14 acyclovir trials by Crooks et al,6 who found a prevalence of
22% among placebo-treated patients. Our prevalence also fell
within the range of 6.2–32.0% reported in Italian studies.7-9
Likewise, our estimate of the 1-year increase in the odds of
developing PHN is in line with previously reported results
(3–12%). Like most earlier studies,3 ours was not able to find a
significant main effect of sex on PHN.
One possible limitation of this study is that the diagnosis of
PHN was made by General Practitioners (GPs); therefore,
some degree of variability was likely, since no unique definition
exists. However, the very recent systematic review and meta-
analysis of risk factors for PHN did not find any association
between age and sex effects and PHN definition. 3 Moreover,
the retrospective study design, with its known limitations, and
the relatively small sample size make it essential to confirm our
findings in larger prospective studies.
In conclusion, in this study, the age-by-sex interaction in the
development of PHN in HZ patients was established, which
suggests that the effect of age on the development of PHN may
differ between males and females. Interaction terms should be
considered in future risk prediction models.
Materials and methods
This retrospective study was formally approved by the Ethics
Committee of S. Martino Hospital (Genoa, Italy). Adult sub-
jects ( 18 years) of both sexes with a previous history of HZ,
Table 1. Characteristics of study participants.
Characteristic Level n % 95% CI
History of HZ No 240 88.2 83.9–91.5
Yes 26 9.6 6.6–13.6
NA 6 2.2 —
HZ localization Thoracic 109 40.1 34.4–46.0
Cervical-facial 42 15.4 11.6–20.2
Sacral-lumbar 40 14.7 11.0–19.4
Abdominal 43 15.8 12.0–20.6
Limbs 26 9.6 6.6–13.6
Ophthalmic 10 3.7 2.0–6.6
NA 2 0.7 —
Background pathologies Respiratory 24 8.8 6.0–12.8
Cardiovascular 109 40.1 34.4–46.0
Endocrine 41 15.1 11.3–19.8
Gastrointestinal 33 12.1 8.8–16.6
Other 74 27.2 22.3–32.8
Cancer before HZ diagnosis No 235 86.4 81.8–90.0
Yes 35 12.9 9.4–17.4
NA 2 0.7 —
Physical trauma No 247 90.8 86.8–93.7
Yes 23 8.5 5.7–12.4
NA 2 0.7 —
Psychological stress No 200 73.5 68.0–78.4
Yes 72 26.5 21.6–32.0
Systemic antiretroviral treatment No 34 12.5 9.1–17.0
Yes 238 87.5 83.0–90.9
NA D not available.
Figure 1. Effect plot for the interaction of age and sex in the fully adjusted logit
model to predict post-herpetic neuralgia.
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diagnosed by a GP in the previous 10 years, were eligible.
Potentially eligible subjects were enrolled by 46 GPs in 2 north-
ern Italian cities (Genoa and Turin) in 2012–2013. Once
informed consent had been obtained, an ad hoc questionnaire
on each patient’s socio-demographic, anamnestic and clinical
features was administered by GPs.
The study outcome was the presence of PHN after the last
HZ episode. Potential predictors of PHN were: gender, age, his-
tory of HZ (new or relapsing case), HZ localization (thoracic,
cervical-facial, sacral-lumbar, abdominal, limbs, ophthalmic),
background pathologies, oncological history, traumatic physical
and psychological events (grief, separation, personal or family
illness, financial difficulties, job loss, etc.) in the 6 months prior
to the last HZ episode, and systemic antiviral treatment.
For descriptive purposes, categorical variables were
expressed as proportions with 95% confidence intervals (CIs).
The univariable relationship between PHN and sex was evalu-
ated by means of x2 test, and that between PHN and age by
means of t test. The effect size for the latter was quantified by
means of Cohen’s d. Subsequently, multivariable logistic
modeling was undertaken in order to detect any association
between PHN and age and sex. The first model utilised the
independent variables of age and sex and their interaction,
while the second considered all the possible confounders
described above. The continuous variable of age was mean-cen-
tered. All analyses were performed in R environment.
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